To clarify the molecular mechanism underlying the inhibitory effect of SCG2 on tumor angiogenesis, transcriptional profiling indicated that VEGF, which is a promoter of angiogenesis and is defined as a therapeutic target of tumor angiogenesis [10, 26, 27], was inhibited by SCG2 in cancer cells. This evidence concerns the gene VEGFA and neoplasm.